Compare FSI & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | ANVS |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.3M | 60.1M |
| IPO Year | 2000 | 2019 |
| Metric | FSI | ANVS |
|---|---|---|
| Price | $6.52 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 20.2K | ★ 1.3M |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $15,494,325.00 | N/A |
| Revenue This Year | $63.39 | N/A |
| Revenue Next Year | $43.77 | N/A |
| P/E Ratio | $109.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.55 | $1.36 |
| 52 Week High | $11.48 | $5.50 |
| Indicator | FSI | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 60.06 | 44.13 |
| Support Level | $6.35 | $1.56 |
| Resistance Level | $7.40 | $2.67 |
| Average True Range (ATR) | 0.34 | 0.14 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 56.52 | 72.00 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The firm also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.